Skip to main content
. Author manuscript; available in PMC: 2018 Apr 27.
Published in final edited form as: Biol Psychiatry. 2013 May 28;74(8):599–606. doi: 10.1016/j.biopsych.2013.04.007

Table 1.

Demographic and clinical characteristics of the ADHD group who remitted or persistence at the time of study entry and at the time of final assessment.

STUDY ENTRY

ADHD: remitted ADHD persistent

Age (yrs)
Mean (SD)
10.5 (3.3) 10.8 (3.4) t(90)=0.45, p=0.65

Sex
Male: Female
37:18 16:21 χ(l)2=5.2, p=0.03

IQ
Mean (SD)
109 (13) 112 (17) t(84)=0.73, p=0.46

Socioeconomic status
Mean (SD)
45 (21) 42 (21) t(88)=0.73, p=0.46

CBCL attention problems
Mean (SD)
72 (10) 73(6) t(88)=0.77, p=0.44

CBCL externalizing problems 66 (11) 65 (11) t(88)=0.97, p=0.33

FINAL ASSESSMENT

ADHD: remitted ADHD: persistent

Age (yrs) Mean (SD) 24.2 (4.4) 23.1 (4.0) t(90)=1.27, p=0.21

Symptoms

DSM IV symptoms:
Inattention 2.2 (1.5) 6.7 (1.5) t(90)=14.0, p<0.0001
Hyperactivity-impulsivity 1.8 (1.4) 4.4 (2.7) t(90)=5.83, p<0.001

CAARS
Inattention 53 (12) 68(11) t(81)=5.4, p<0.001
Hyperactivity 52 (10) 61(11) t(81)=3.3, p=0.001
Impulsivity 49 (10) 59 (12) t(81)=3.7, p<0.001
Self-concept 49 (11) 60 (12) t(81)=1.9, p=0.06
DSM inattentive 60 (14) 75 (11) t(81)=4.7 p<0.001
DSM hyperactive 53(11) 63(13) t(81)=3.7, p=0.001
DSM total 59 (13) 73 (11) t(81)=4.7, p<0.001

Comorbidity

Any comorbidity Mood: 9 (16%) 12 (32%) Any comorbidity vs none, exact p=0.08
Depression 3 6
Dysthymia 1 3

Anxiety:
GAD 4 2
Anxiety NOS 0 3
OCD 0 1
PTSD 1 1

Psychostimulant medication use

Proportion of study on medication 50% (33%) 59% (29%) t(88)=1.13, p=0.26

Psychostimulant use at follow-up Medicated vs unmedicated χ2=11, p<0.001
Daily 1 (2%) 9 (24%)
Intermittent (<l/wk) 4 (7%) 5 (14%)
None 50 (91%) 23 (62%)